Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial-Reference-Cited by-同舟云学术

Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial

Published:2021-04 Issue: Volume:154 Page:5-12
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Katz Sharyn I.,Roshkovan Leonid^ORCID,Berger Ian,Friedberg Joseph S.,Alley Evan W.^ORCID,Simone Charles B.^ORCID,Haas Andrew R.,Cengel Keith A.,Sterman Daniel H.,Albelda Steven M.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference43 articles.

1. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients;Ho;Clin. Cancer Res.,2005

2. Novel antibody therapeutics targeting mesothelin in solid tumors;Zhao;Clin. Cancer Drugs,2016

3. Mesothelin immunotherapy for cancer: ready for prime time?;Hassan;J. Clin. Oncol.,2016

4. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer;Cristaudo;Clin. Cancer Res.,2007

5. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study;Roe;Lung Cancer,2008

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy in Mesotheliomas: Uphill All the Way;Cancers;2024-05-22

2. Mesothelin-targeted MRI for assessing migration, invasion, and prognosis in malignant pleural mesothelioma;Cancer Nanotechnology;2024-01-05

3. Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers;Journal of Clinical Medicine;2023-11-09

4. Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy;Immunity;2023-10

5. Longitudinal monitoring of response to chemotherapy in patients with malignant pleural mesothelioma by biomarkers;Cancer Biomarkers;2023-09-05